A Phase 3 interventional study of Dupilumab and Placebo in Eosinophilic Esophagitis, sponsored by Regeneron Pharmaceuticals. Completed at 95 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing dupilumab in Eosinophilic Esophagitis — 4 open to participants now, 7 under way, 1 of them phase 3. dupilumab · Eosinophilic Esophagitis.
Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, this one has the largest enrollment, is the only one that started in 2018, is one of 3 in phase 3, and was the 2nd registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →4 of the 11 studies testing dupilumab in Eosinophilic Esophagitis are open now, in 1 country. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 6 mo–6 yrs
University of Colorado, Denver · Sites in United States
Ages 12–25
University of California, San Diego · Sites in United States
Ages 22+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 47 across the 11 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 7 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study by study part are:
Part A:
To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures and to inform/confirm the final sample size determination for Part B.
Part B:
To demonstrate the efficacy of dupilumab treatment compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures.
Part C:
To assess the safety and efficacy of dupilumab treatment in adult and adolescent patients with EoE after up to 52 weeks of treatment as assessed by histological and clinical measures.
The secondary objectives of the study are:
Key Inclusion Criteria (Parts A \& B):
Key Exclusion Criteria (Parts A \& B):
Key Exclusion Criteria (Part C):
Note: Other inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
Drug: Dupilumab · Drug: Placebo
Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
Drug: Dupilumab · Drug: Placebo
Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
Drug: Dupilumab
Solution for injection administered subcutaneously
Also known as: DUPIXENT, REGN668, SAR231893
Matching placebo
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
Time frame: At week 24
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Time frame: Baseline and week 24
Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.
Time frame: Baseline and week 24
Percent Change From Baseline in DSQ Total Score at Week 24
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Time frame: Baseline and week 24
Absolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
Time frame: Baseline and week 24
Absolute Change From Baseline in EoEHSS Mean Stage Score at Week 24
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
Time frame: Baseline and week 24
Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24
EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.
Time frame: Baseline and week 24
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 24
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
Time frame: At week 24
Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
Time frame: Baseline and week 24
NES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
Time frame: Baseline and week 24
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 24
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
Time frame: At week 24
Absolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24
The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.
Time frame: Baseline and week 24
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.
Time frame: Baseline and week 24
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.
Time frame: Baseline and week 24
Percentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 24
Time frame: At week 24
Absolute Change From Baseline in Esophageal Distensibility Plateau Measured by Functional Lumen Imaging, if Collected, at Week 24
Time frame: At week 24
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 52
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
Time frame: At week 52
Absolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Time frame: Baseline (of previous study part) and week 52
Percent Change in DSQ Total Score at Week 52
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Time frame: Baseline (of previous study part) and week 52
Absolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52
EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.
Time frame: Baseline (of previous study part) and week 52
Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.
Time frame: Baseline (of previous study part) and week 52
Absolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
Time frame: Baseline (of previous study part) and week 52
Absolute Change in EoEHSS Mean Stage Score at Week 52
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
Time frame: Baseline (of previous study part) and week 52
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 52
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
Time frame: At week 52
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 52
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
Time frame: At week 52
Absolute Change in Health-related QOL as Measured by EoE-IQ at Week 52
The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.
Time frame: Baseline (of previous study part) and week 52
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.
Time frame: Baseline (of previous study part) and week 52
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.
Time frame: Baseline (of previous study part) and week 52
Percentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period
Time frame: Baseline (of Part C) to week 28
NES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
Time frame: Baseline (of previous study part) and week 52
NES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
Time frame: Baseline (of previous study part) and week 52
Concentration of Functional Dupilumab in Serum at Week 52
Time frame: Baseline (of Part C) up to week 52
Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response
Number of treatment-emergent ADA responses to dupilumab reported.
Time frame: Baseline (of previous study part) up to week 52
| Milestone | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 39 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 36 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Week 24 not performed due to coronavirus disease-2019 (covid-19) | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unconfirmed early termination visit | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 79 | 81 | 80 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 74 | 79 | 75 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 5 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 restrictions | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject randomized, but did not receive study drug; did not qualify for study | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 37 | 40 | 37 | 37 | 79 | 74 |
| Completed week 52 (end of treatment) | 0 | 0 | 0 | 0 | 0 | 32 | 38 | 34 | 36 | 74 | 65 |
| Completed | 0 | 0 | 0 | 0 | 0 | 30 | 35 | 33 | 36 | 67 | 64 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 7 | 5 | 4 | 1 | 12 | 10 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 1 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 0 | 7 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Covid-19 related | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
| Percentage of Participants | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24 | 5.1 (0.63 to 17.32) | 59.5 (43.28 to 74.37) | 6.3 (2.09 to 14.16) | 60.5 (49.01 to 71.19) | 58.8 (47.18 to 69.65) |
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24 | -9.60 (-15.056 to -4.136) | -21.92 (-26.870 to -16.967) | -13.86 (-17.605 to -10.120) | -14.37 (-18.018 to -10.723) | -23.78 (-27.427 to -20.131) |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.
| Percentage of Change | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24 | -2.98 (-17.886 to 11.921) | -71.24 (-84.863 to -57.613) | 8.38 (-11.677 to 28.433) | -70.84 (-87.095 to -54.585) | -80.24 (-96.589 to -63.895) |
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
| Percentage of Change | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Percent Change From Baseline in DSQ Total Score at Week 24 | -31.68 (-47.545 to -15.818) | -69.17 (-83.578 to -54.752) | -41.43 (-51.749 to -31.116) | -45.78 (-55.658 to -35.904) | -64.32 (-74.267 to 54.382) |
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24 | -0.001 (-0.1166 to 0.1139) | -0.761 (-0.8732 to -0.6484) | -0.148 (-0.2379 to -0.0584) | -0.814 (-0.8958 to -0.7317) | -0.830 (-0.9136 to -0.7463) |
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in EoEHSS Mean Stage Score at Week 24 | -0.012 (-0.1243 to 0.0995) | -0.753 (-0.8627 to -0.6441) | -0.132 (-0.2179 to -0.0464) | -0.793 (-0.8713 to -0.7144) | -0.804 (-0.8839 to -0.7237) |
EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24 | -0.3 (-1.11 to 0.50) | -3.2 (-3.98 to -2.38) | -0.6 (-1.37 to 0.12) | -4.6 (-5.24 to -3.89) | -4.5 (-5.17 to -3.77) |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
| Percentage of Participants | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 24 | 7.7 (1.62 to 20.87) | 64.3 (48.03 to 78.45) | 7.6 (2.84 to 15.80) | 79.0 (68.54 to 87.27) | 82.5 (72.38 to 90.09) |
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24 | -0.160 | -2.660 | -0.730 | -2.675 | -2.665 |
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| NES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24 | -0.320 | -1.970 | -0.640 | -1.950 | -1.930 |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
| Percentage of Participants | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 24 | 0.0 (0.00 to 9.03) | 21.4 (10.30 to 36.81) | 1.3 (0.03 to 6.85) | 27.2 (17.87 to 38.19) | 28.8 (19.18 to 39.95) |
The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24 | -0.246 (-0.4659 to -0.0266) | -0.614 (-0.8140 to -0.4149) | -0.578 (-0.6977 to -0.4585) | -0.593 (-0.7152 to -0.4706) | -0.887 (-1.0050 to -0.7685) |
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24 | -3.9 (-5.46 to -2.31) | -5.8 (-7.24 to -4.44) | -4.0 (-5.16 to -2.80) | -4.5 (-5.59 to -3.32) | -5.4 (-6.60 to 4.27) |
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.
| Score on a Scale | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24 | -1.7 (-2.67 to -0.71) | -3.4 (-4.29 to -2.53) | -2.6 (-3.25 to -1.87) | -3.0 (-3.69 to -2.36) | -3.9 (-4.61 to -3.25) |
| Percentage of Participants | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW |
|---|---|---|---|---|---|
| Percentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 24 | 12.8 (4.30 to 27.43) | 0.0 (0.00 to 8.41) | 2.5 (0.31 to 8.85) | 1.2 (0.03 to 6.69) | 2.5 (0.30 to 8.74) |
No measurements were reported for this outcome.
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
| Percentage of Participants | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 52 | 60.0 | 55.9 | 71.9 | 67.6 | 74.0 | 84.6 |
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52 | -21.71 ± 17.143 | -23.44 ± 16.149 | -23.69 ± 13.737 | -27.25 ± 11.457 | -20.87 ± 16.387 | -30.26 ± 15.389 |
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
| Percentage of Change | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Percent Change in DSQ Total Score at Week 52 | -65.87 ± 49.705 | -75.93 ± 36.892 | -71.01 ± 37.256 | -78.13 ± 31.003 | -61.19 ± 44.447 | -80.74 ± 32.866 |
EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52 | -3.9 ± 2.74 | -4.1 ± 3.37 | -4.3 ± 3.21 | -6.1 ± 3.60 | -5.2 ± 3.40 | -5.3 ± 2.85 |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.
| Percentage of Change | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52 | -83.76 ± 24.996 | -88.59 ± 13.506 | -91.20 ± 13.037 | -84.21 ± 42.169 | -84.78 ± 40.973 | -95.85 ± 4.037 |
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52 | -0.873 ± 0.5506 | -0.873 ± 0.3537 | -0.779 ± 0.4292 | -0.906 ± 0.3936 | -0.838 ± 0.4039 | -0.968 ± 0.4293 |
Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change in EoEHSS Mean Stage Score at Week 52 | -0.874 ± 0.4630 | -0.891 ± 0.2770 | -0.710 ± 0.3783 | -0.871 ± 0.3510 | -0.809 ± 0.3434 | -0.932 ± 0.3730 |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
| Percentage of Participants | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 52 | 70.0 | 82.4 | 87.5 | 78.4 | 83.6 | 100 |
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).
| Percentage of Participants | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 52 | 26.7 | 29.4 | 40.6 | 16.2 | 31.5 | 30.8 |
The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change in Health-related QOL as Measured by EoE-IQ at Week 52 | -0.954 ± 0.6690 | -0.911 ± 0.6344 | -1.021 ± 0.7169 | -0.858 ± 0.6360 | -0.773 ± 0.6217 | -0.935 ± 0.6883 |
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52 | -7.2 ± 6.46 | -5.9 ± 6.80 | -6.2 ± 6.42 | -5.9 ± 6.47 | -4.7 ± 5.99 | -6.4 ± 6.86 |
The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52 | -4.3 ± 3.78 | -3.2 ± 3.50 | -4.0 ± 3.54 | -3.8 ± 3.62 | -3.6 ± 3.45 | -4.7 ± 4.03 |
| Percentage of Participants | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period | 8.1 | 0 | 2.7 | 2.7 | 0 | 1.4 |
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| NES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52 | -2.580 (-2.87 to -0.45) | -2.670 (-2.83 to -1.09) | -2.28 (-2.8 to -0.8) | -2.62 (-2.9 to -2.1) | -2.64 (-2.9 to 1.2) | -2.69 (-2.9 to -0.6) |
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).
| Score on a Scale | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| NES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52 | -1.940 (-2.11 to -0.42) | -1.970 (-2.07 to -0.95) | -1.76 (-2.1 to -1.0) | -1.96 (-2.1 to -1.5) | -1.95 (-2.1 to 0.3) | -1.97 (-2.2 to -0.7) |
| milligrams per liter (mg/L) | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|
| Week 32 | 101 ± 44.6 | 205 ± 76.8 | 46.0 ± 33.1 | 124 ± 56.7 | 74.0 ± 42.0 | 195 ± 94.6 |
| Week 52 | 137 ± 81.6 | 152 ± 70.2 | 58.6 ± 36.5 | 151 ± 96.0 | 68.9 ± 45.7 | 176 ± 120 |
Number of treatment-emergent ADA responses to dupilumab reported.
| Events | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Part A/C: Placebo / Dupilumab 300 mg QW | Part A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW | Part B/C: Placebo / Dupilumab 300 mg Q2W | Part B/C: Placebo / Dupilumab 300 mg QW | Part B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2W | Part B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response | 0 | 0 | 0 | 2 | 1 | 4 | 1 | 1 | 0 | 5 | 0 |
Collected over From day of first dose up to 12 weeks after end of treatment visit (week 52). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | 0/39 (0%) | 2/39 (5.1%) | 28/39 (71.8%) |
| Part A: Dupilumab 300 mg QW | 0/42 (0%) | 2/42 (4.8%) | 26/42 (61.9%) |
| Part B: Placebo | 0/78 (0%) | 1/78 (1.3%) | 41/78 (52.6%) |
| Part B: Dupilumab 300 mg Q2W | 0/81 (0%) | 2/81 (2.5%) | 57/81 (70.4%) |
| Part B: Dupilumab 300 mg QW | 0/80 (0%) | 5/80 (6.3%) | 50/80 (62.5%) |
| Part C: Dupilumab 300 mg Q2W (Placebo in Part B) | 0/37 (0%) | 1/37 (2.7%) | 19/37 (51.4%) |
| Part C: Dupilumab 300 mg QW (Placebo in Part A or B) | 0/74 (0%) | 3/74 (4.1%) | 44/74 (59.5%) |
| Part C: Dupilumab 300 mg Q2W (Part B Regimen Continued) | 0/79 (0%) | 1/79 (1.3%) | 47/79 (59.5%) |
| Part C: Dupilumab 300 mg QW (Part A or B Regimen Continued) | 0/114 (0%) | 4/114 (3.5%) | 62/114 (54.4%) |
| Event | Part A: Placebo | Part A: Dupilumab 300 mg QW | Part B: Placebo | Part B: Dupilumab 300 mg Q2W | Part B: Dupilumab 300 mg QW | Part C: Dupilumab 300 mg Q2W (Placebo in Part B) | Part C: Dupilumab 300 mg QW (Placebo in Part A or B) | Part C: Dupilumab 300 mg Q2W (Part B Regimen Continued) | Part C: Dupilumab 300 mg QW (Part A or B Regimen Continued) |
|---|---|---|---|---|---|---|---|---|---|
| Open globe injuryInjury, poisoning and procedural complications | 0/39 | 0/42 | 0/78 | 0/81 | 0/80 | 1/37 | 0/74 | 0/79 | 0/114 |
| Suicidal ideationPsychiatric disorders | 1/39 | 0/42 | 0/78 | 2/81 | 0/80 | 0/37 | 0/74 | 0/79 | 0/114 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/39 | 0/42 | 0/78 | 0/81 | 0/80 | 0/37 | 0/74 | 0/79 | 0/114 |
| Abdominal painGastrointestinal disorders | 0/39 | 1/42 | 0/78 | 0/81 | 0/80 | 0/37 | 0/74 | 0/79 | 0/114 |
| Uterine polypReproductive system and breast disorders | 0/39 | 1/42 | 0/78 | 0/81 | 0/80 | 0/37 | 0/74 | 0/79 | 0/114 |
| VomitingGastrointestinal disorders | 0/39 | 0/42 | 0/78 | 0/81 | 0/80 | 0/37 | 1/74 | 0/79 | 0/114 |
| Systemic inflammatory response syndromeGeneral disorders | 0/39 | 0/42 | 0/78 | 0/81 | 0/80 | 0/37 | 1/74 | 0/79 | 0/114 |
| CellulitisInfections and infestations | 0/39 | 0/42 | 0/78 | 0/81 | 0/80 | 0/37 | 1/74 | 0/79 | 0/114 |
| Mental status changesPsychiatric disorders | 0/39 | 0/42 | 1/78 | 0/81 | 0/80 | 0/37 | 0/74 | 0/79 | 0/114 |
| Generalised anxiety disorderPsychiatric disorders | 0/39 | 0/42 | 0/78 | 0/81 | 0/80 | 0/37 | 0/74 | 1/79 | 0/114 |
| Event | Part A: Placebo | Part A: Dupilumab 300 mg QW | Part B: Placebo | Part B: Dupilumab 300 mg Q2W | Part B: Dupilumab 300 mg QW | Part C: Dupilumab 300 mg Q2W (Placebo in Part B) | Part C: Dupilumab 300 mg QW (Placebo in Part A or B) | Part C: Dupilumab 300 mg Q2W (Part B Regimen Continued) | Part C: Dupilumab 300 mg QW (Part A or B Regimen Continued) |
|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 6/39 | 4/42 | 9/78 | 18/81 | 8/80 | 2/37 | 6/74 | 6/79 | 10/114 |
| Injection site reactionGeneral disorders | 5/39 | 9/42 | 16/78 | 18/81 | 16/80 | 3/37 | 12/74 | 14/79 | 14/114 |
| Injection site swellingGeneral disorders | 1/39 | 5/42 | 2/78 | 7/81 | 10/80 | 4/37 | 0/74 | 2/79 | 4/114 |
| Injection site painGeneral disorders | 3/39 | 5/42 | 4/78 | 10/81 | 7/80 | 4/37 | 6/74 | 6/79 | 9/114 |
| NasopharyngitisInfections and infestations | 4/39 | 5/42 | 3/78 | 4/81 | 2/80 | 2/37 | 7/74 | 2/79 | 5/114 |
| HeadacheNervous system disorders | 4/39 | 2/42 | 9/78 | 5/81 | 7/80 | 2/37 | 4/74 | 4/79 | 5/114 |
| Blood creatine phosphokinase increasedInvestigations | 2/39 | 0/42 | 1/78 | 1/81 | 3/80 | 4/37 | 3/74 | 2/79 | 2/114 |
| Eosinophilic oesophagitisGastrointestinal disorders | 0/39 | 0/42 | 0/78 | 0/81 | 0/80 | 4/37 | 0/74 | 0/79 | 0/114 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 4/39 | 0/42 | 1/78 | 0/81 | 0/80 | 0/37 | 1/74 | 1/79 | 2/114 |
| RashSkin and subcutaneous tissue disorders | 4/39 | 0/42 | 0/78 | 4/81 | 3/80 | 1/37 | 0/74 | 2/79 | 7/114 |
Part A Full analysis set (FAS) includes all randomized participants in Part A; Part B FAS includes all randomized participants in Part B. Participants who participated in Part A were not eligible to participate in Part B.
| Age, Customized(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| ≥ 12 to < 18 years old | 9 | 11 | — | — | — | 20 |
| ≥ 18 to < 40 years old | 22 | 13 | — | — | — | 35 |
| ≥ 40 to < 65 years old | 8 | 18 | — | — | — | 26 |
| ≥ 65 years old | 0 | 0 | — | — | — | 0 |
| Age, Customized(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| ≥ 12 to < 18 years old | — | — | 26 | 27 | 26 | 79 |
| ≥ 18 to < 40 years old | — | — | 38 | 35 | 38 | 111 |
| ≥ 40 to < 65 years old | — | — | 15 | 18 | 15 | 48 |
| ≥ 65 years old | — | — | 0 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| Female | 18 | 14 | — | — | — | 32 |
| Male | 21 | 28 | — | — | — | 49 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| Female | — | — | 21 | 36 | 30 | 87 |
| Male | — | — | 58 | 45 | 50 | 153 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 4 | — | — | — | 5 |
| Not Hispanic or Latino | 38 | 38 | — | — | — | 76 |
| Unknown or Not Reported | 0 | 0 | — | — | — | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | — | — | 5 | 3 | 5 | 13 |
| Not Hispanic or Latino | — | — | 74 | 77 | 75 | 226 |
| Unknown or Not Reported | — | — | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| White | 37 | 41 | — | — | — | 78 |
| Black or African American | 1 | 1 | — | — | — | 2 |
| Asian | 0 | 0 | — | — | — | 0 |
| Other | 1 | 0 | — | — | — | 1 |
| Not reported | 0 | 0 | — | — | — | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Dupilumab 300 mg SC QW | Part B: Placebo | Part B: Dupilumab 300 mg SC Q2W | Part B: Dupilumab 300 mg SC QW | Total |
|---|---|---|---|---|---|---|
| White | — | — | 72 | 74 | 71 | 217 |
| Black or African American | — | — | 3 | 3 | 2 | 8 |
| Asian | — | — | 1 | 1 | 3 | 5 |
| Other | — | — | 2 | 2 | 3 | 7 |
| Not reported | — | — | 1 | 1 | 1 | 3 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Sep 2021, 35 months.
Results were first posted in Dec 2022, 1 year 3 months after primary completion.
Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab